Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 May;12(3):276-282.
doi: 10.1111/cts.12609. Epub 2019 Feb 12.

Impact of Insulin Tregopil and Its Permeation Enhancer on Pharmacokinetics of Metformin in Healthy Volunteers: Randomized, Open-Label, Placebo-Controlled, Crossover Study

Affiliations
Clinical Trial

Impact of Insulin Tregopil and Its Permeation Enhancer on Pharmacokinetics of Metformin in Healthy Volunteers: Randomized, Open-Label, Placebo-Controlled, Crossover Study

Anand Khedkar et al. Clin Transl Sci. 2019 May.

Abstract

Oral insulin tregopil (IN-105; a new drug under development) may be coadministered with oral antidiabetic drugs, such as metformin in patients with type 2 diabetes mellitus for optimal glycemic control. IN-105 has sodium caprate excipient, a permeation enhancer, for enhancing absorption in the stomach and increasing bioavailability via an oral route. Sodium caprate may increase bioavailability of metformin by a similar mechanism. Therefore, it was necessary to study the effect of IN-105 on pharmacokinetics (PKs) of metformin. In this randomized, open-label, cross-over study, metformin was administered to healthy volunteers receiving IN-105/placebo under fed/fasting conditions. The 90% confidence interval (CI) of the geometric mean ratio of the area under the curve from time zero to infinity (AUC0-inf ; fasting and fed) and peak plasma concentration (Cmax ; fed) of metformin were within 0.80-1.25 acceptance range. Under fasting conditions, the upper bound margin of Cmax was just beyond this range (i.e., 1.27) and was concluded as functionally not relevant. There was no clinically significant effect of sodium caprate/IN-105 on PKs of metformin under fasting/fed conditions, and it was safe.

PubMed Disclaimer

Conflict of interest statement

Drs Anand Khedkar and Vinu Jose were employees of Biocon Research Ltd. at the time of study conduct. Dr Harold Lebovitz is a scientific advisor for Biocon, Intarcia Pharmaceuticals, Metacure Ltd., and Poxel Pharmaceuticals. He holds stocks in Abbott, AbbVie, Inc., General Electric, Gilead Sciences, Inc., IBM, Nestlé, and Novartis AG. Dr Alan D. Cherrington is a scientific advisor for Biocon, Fractyl Laboratories, Inc., Metavention, and NuSirt Biopharma, Inc., Sensulin Labs, LLC., These Three Medical, Inc. (T3M), VTV Therapeutics, and Zafgen. He is a consultant at Abvance, Boston Scientific Corporation, California Institute for Biomedical Research (Calibr), Eli Lilly and Company, Galvani Bioelectronics Limited, MedImmune, Novo Nordisk Inc., Silver Lake, Thermalin Diabetes, LLC., Thetis Pharmaceuticals LLC., and VTV Therapeutics. He has received research support from Boston Scientific Corporation, Galvani Bioelectronics Limited, Novo Nordisk, Inc., Silver Lake, and Zafgen, and holds stocks in Fractyl Laboratories, Inc., Metavention, Thetis Pharmaceuticals LLC., and Zafgen and has professional relationships with Abvance, Sensulin Labs, LLC. Dr Alexander Fleming is a board member of Tolerion and Innoneo. He is a consultant at Acasti, Adocia, Biocon, Cardiora, Carthera, Casebia, Diamyd, Diasome, Dance, EnteraBio, Emperra, Fractyl, G‐Medical, Immune Pharma, InsuLine Medical, Intarcia Therapeutics, Intra‐Cellular Therapeutics, InClinica, Ipsen Biopharmaceuticals, Lexicon, Mars Symbioscience, Mediwound, Merck KGaA, Mediwound, Metronom, Mylan, Neovii, NuSirt Biopharma, Orgenesis, Oramed, Permeatus, ProSciento, RenovoRx, Rhythm Pharmaceuticals, Sanofi, Serpin, SkinJect, Suzhou Connect, Thermalin, ThermoFisher, Upkara, Veracyte, VeroScience, Xeris Pharmaceuticals, and Zucara. Dr Sandeep N. Athalye is an employee of Biocon Research Limited and holds stocks in Biocon. Dr Ashwini Vishweswaramurthy is an employee of Biocon Research Limited.

Figures

Figure 1
Figure 1
Study design.
Figure 2
Figure 2
Mean (± SD) plasma metformin concentrations (semilog) vs. time after oral administration in healthy volunteers by treatment in cohort 1.
Figure 3
Figure 3
Mean (± SD) plasma metformin concentrations (semilog) vs. time after oral administration in healthy volunteers by treatment in cohort 2.
Figure 4
Figure 4
Geometric mean ratio and 90% confidence interval (CI) for metformin in cohorts 1 and 2. AUC, area under the curve; AUCinf, AUC from time zero to infinity; Cmax, peak plasma concentration IN‐105, insulin tregopil.

References

    1. Arbit, E. & Kidron, M. Oral insulin delivery in a physiologic context: review. J. Diabetes Sci. Technol. 11, 825–832 (2017). - PMC - PubMed
    1. Khedkar, A. et al A dose range finding study of novel oral insulin (IN‐105) under fed conditions in type 2 diabetes mellitus subjects. Diabetes Obes. Metab. 12, 659–664 (2010). - PubMed
    1. Guimarães, C. , Marra, C.A. , Gill, S. , Meneilly, G. , Simpson, S. & Godoy, A.L. Exploring patients’ perceptions for insulin therapy in type 2 diabetes: a Brazilian and Canadian qualitative study. Patient Prefer. Adherence 4, 171 (2010). - PMC - PubMed
    1. Anderberg, E. , Lindmark, T. & Artursson, P. Sodium caprate elicits dilatations in human intestinal tight junctions and enhances drug absorption by the paracellular route. Pharm. Res. 10, 857–864 (1993). - PubMed
    1. Han, T. , Proctor, W.R. , Costales, C.L. , Cai, H. , Everett, R.S. & Thakker, D.R. Four cation‐selective transporters contribute to apical uptake and accumulation of metformin in caco‐2 cell monolayers. J. Pharmacol. Exp. Ther. 352, 519–528 (2015). - PMC - PubMed

Publication types

LinkOut - more resources